Correction to: Blood Cancer Journal https://doi.org/10.1038/s41408-023-00797-8, published online 09 May 2023
In the sentence beginning ‘Isa is approved in multiple countries...’ in ‘Introduction’, the term ‘treatment lines’ should have read ‘therapies’. The full text is as follows.
Isa is approved in multiple countries in combination with pomalidomide and low-dose dexamethasone for patients with RRMM after ≥2 prior therapies, based on the results of the randomized Phase 3 ICARIA-MM study.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Martin, T., Dimopoulos, MA., Mikhael, J. et al. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 13, 152 (2023). https://doi.org/10.1038/s41408-023-00923-6
Published:
DOI: https://doi.org/10.1038/s41408-023-00923-6
